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I. INTRODUCTION
Kathy Hopkins was the eldest of seven children. She was a single mother, and
the sole supporter of her son. In the spring of 2007, Kathy was diagnosed with stage
four glioblastoma multiform (“GBM”). GBM is a compilation of small tumors
within the glia or the precursors of the glia within the central nervous system.1 This
form of brain cancer is “the most aggressive of the glimoas.”2 Most individuals with
* J.D. Cleveland State University, Cleveland-Marshall College of Law, 2013; B.S. John
Carroll University, 2010. Thank you to my loving family and friends for their continuous
support. A special thank you to Lisa Gasbarre Black, Esq., my mentor and dear friend. Lastly,
I would like to dedicate this Note to the memory of my beloved Aunt Katherine Hopkins.
1

Eric C. Holland, Glioblastoma Multiforme: The Terminator, 97(12) PNAS 6242, 6242
(2000), available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC33993/pdf/pq006242.pdf.
2

Id. The medical community has “evaded increasingly clever and intricate attempts at
therapy over the last half-century.” Id. The latest treatment implements “a hybrid virus that
infects and kills clonal human glioma cell lines.” Id. This treatment has been tested in athymic
mice successfully “without affecting nonneoplastic cells within the brain.” Id.
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GBM die in less than a year from the date of diagnosis.3 Even with treatment, the
life expectancy of individuals diagnosed with GBM only increases from two months
to a year.4 Kathy’s tumor was inoperable. Her only options for treatment included
chemotherapy and radiation. Determined that the medical community would
discover a cure, Kathy chose to try every medical procedure available in hopes that
she could defeat GBM. On April 1, 2009, two years after her diagnosis, at the age of
63, Kathy passed away surrounded by her loving family.5
Greg Knittel was the Classics’ Chairman, Dean of Teachers, and founding soccer
coach at St. Ignatius High School in Cleveland, Ohio.6 Greg, fondly known by his
students and the Ignatius community as “Doc,” was forced to retire from St. Ignatius
when he lost the ability to control his car on his drive into work.7 Greg was
suffering from amyotrophic lateral sclerosis (“ALS”).8 The major cause(s) of ALS,
also commonly referred to as Lou Gehrig’s9 disease, are unknown.10 Ten percent of
all ALS cases are genetically based.11 ALS causes neurons12 to slowly waste away
3

Id.

4

Id.

5

The story of Kathy Hopkins was taken from the author’s personal experiences.

6

Grant Segall, Greg Knittel was Dean, Chairman and Soccer Coach at St. Ignatius:
News Obituary, CLEVELAND PLAIN DEALER, Feb. 8, 2013, http://www.cleveland.com/obitu
aries/index.ssf/2013/02/greg_knittel_was_dean_chairman.html (last visited Feb. 17, 2013).
Greg had an extensive educational and extracurricular background. Id.
He attended College of the Holy Cross in Worcester, Mass. He earned a bachelor’s
degree from John Carroll University and went on to a master’s at the University of
California at Santa Barbara. He taught at high school in Santa Barbara for two years.
Knittel rejoined Ignatius in 1974 to teach classics and started the soccer team two
years later. He stopped coaching in 1985 to earn a doctorate from Kent State
University. He coached again from 1990 through 1994. His teams had 161 wins, 61
losses and 31 ties. He was inducted into the school’s Athletic Hall of Fame twice: as
coach and as part of the 1964 football team, which was inducted as a group. He was
twice named area soccer coach of the year and once Ignatius’ teacher of the year.
Id.
7

Id.

8

Gregory Joseph “Doc” Knittel Ph.D, Obituaries & Guestbook, CLEVELAND PLAIN
DEALER, Feb 8, 2013, http://obits.cleveland.com/obituaries/cleveland/obituary.aspx?n=gre
gory-joseph-knittel-doc&pid=162929249&fhid=15566#fbLoggedOut; Amyotrophic Lateral
Sclerosis: Lou Gehrig’s Disease; ALS; Upper and Lower Motor Neuron Disease; Motor
neuron disease, PUBMED HEALTH, http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001708/
(last updated Aug. 26, 2012).
9
Henry Louis Gehrig played for the New York Yankees during the 1920s and 1930s.
Lou Gehrig, BIOGRAPHY.COM, http://www.biography.com/people/lou-gehrig-9308266?page=1
(last visited Feb. 17, 2013). A member of the Baseball Hall of Fame, Gehrig as a Yankees first
basemen set the mark for consecutive games played until he was forced to retire due to ALS.
Id. “His diagnosis with the disease helped put the spotlight on the condition, and in the years
since Gehrig's passing, it has come to be known popularly as ‘Lou Gehrig's disease.’” Id.
10

Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8.

11

Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8.
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and eventually die, resulting in “muscle weakening, twitching, and eventually the
inability to move the arms, legs, and body.”13 This is caused by the inability of
neurons to “send messages to [the] muscles” of the body after neurons have died.14
Individuals with ALS typically die within three to five years after being diagnosed.15
Only about twenty five percent of individuals diagnosed with ALS live beyond five
years.16 On February 5, 2013 Greg “Doc” Knittel passed away surrounded by his
loving family.17
Kathy and Greg are only two individuals, out of millions, who have suffered or
who are currently suffering from incurable diseases. Scientists are in a race to
discover new diagnostic technologies and treatments to bring an end to human
anguish through the rapidly growing field of genetics. While cures are within the
grasp of humanity’s fingertips, current gene patent regulations act as roadblocks to
12
A neuron is “[a]ny of the impulse-conducting cells that constitute the brain, spinal
column, and nerves, consisting of a nucleated cell body with one or more dendrites and a
single axon. Also called nerve cell.” Neuron, FREE ONLINE DICTIONARY, THESAURUS, AND
ENCYCLOPEDIA, http://www.thefreedictionary.com/neuron (last visited Nov. 24, 2011).
13

Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8.

14

Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8.

15

Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8.

16

Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8.

17

The story of Greg “Doc” Knittel was taken from the author’s personal experiences.
Another ALS story is that of Jim Ziegler:
Jim Ziegler was a humble, generous man who made his mark on the world for the 62
years he was a part of it. In the summer of 2010, Jim began experiencing muscle
pains in his legs, particularly when engaging in physical activity. On one occasion, his
friends had to carry him off the golf course because the pain became so severe that it
was unbearable for Jim to walk. Jim visited his doctor that fall and spoke of the
symptoms he had been experiencing, and it was on that day that his fate was
confirmed. At the age of 61, my uncle was diagnosed with ALS. Jim’s diagnosis came
in September of 2010, and he passed away on April 29, 2011. The case my uncle
suffered from was especially aggressive, and stole his ability to walk or even move his
arms and legs within a few months of his diagnosis. For as much pain and suffering
that he went through with this terrible disease, Jim was incredibly patient and willing
to accept his fate. For as quickly as the disease progressed through Jim’s body, it took
him away from us just as swiftly. In honor of Jim Ziegler and the legacy he left
behind, our family has participated in the Walk to Defeat ALS in hopes of
contributing to fund future research that will find a will cure to this debilitating and
fatal disease.
Interview with Riannon Ziegler, Third Year Law Student, Cleveland-Marshall College of
Law, Cleveland State University, Cleveland, Ohio (Jan. 13, 2013). The ALS Association is
one of “the largest privately-funded research enterprise[s] engaged to uncover the mystery of
a disease that affects as many as 30,000 annually.” About Us, Walk to Defeat ALS, THE ALS
ASSOCIATION, http://web.alsa.org/site/PageServer?pagename=WLK_BP_aboutus (last visited
Feb. 18, 2013). Over the past 10 years, the ALS Association has contributed about forty-eight
million dollars to research. Id. “The ALS Association symbolizes the hopes of people
everywhere that [ALS] will one day be a disease of the past relegated to historical status,
studied in medical textbooks, conquered by the dedication of thousands who have worked
ceaselessly to understand and eradicate this perplexing killer.” Id.
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uncovering such discoveries. Gene patents have long been a topic of debate, first
with the discovery of DNA, and later with the Human Genome Project and the
HapMap Project, which resulted in the discovery of the complete sequence of the
human genome and further discoveries of gene sequences.18
In September, 2011, the Senate passed H.R. 1249, the Leahy-Smith America
Invents Act (“AIA”), which President Barrack Obama signed into law on September
16th.19 The AIA is the largest transformation to U.S. patent law since 1952.20 While
the new legislation implements numerous, positive changes to the U.S. patent
system, it fails to address any of the concerns raised by gene patent critics over the
past few decades.21 Gene patents should be categorized as patentable subject matter
within the AIA, but under a separate patent category with specifically engineered
regulations designed to promote scientific research and collaboration that will in turn
foster quicker results in diagnostic technologies and treatments.
Part I of this Note provides an educational background on genetics. Part II
provides a background on the U.S. patent system, taking a historical look at patent
legislation and case law, as well as the societal views surrounding gene patents. In
general, this section analyzes the debate on whether genetic materials are patentable
subject matter within the scope of 35 U.S.C. § 101. Part III lays a foundation of the
AIA, and examines whether the new patent legislation properly regulates gene
patents to stimulate and regulate scientific research and development. Part IV
analyzes the need for new regulations specifically designed for gene patents within
the AIA, and proposes detailed guidelines to achieve stricter, more appropriate
regulations for gene patents.

18
International Consortium Launches Genetic Variation Mapping Project: HapMap will
Help Identify Genetic Contributions to Common Diseases, NATIONAL HUMAN GENOME
RESEARCH INSTITUTE, http://www.genome.gov/10005336 (last visited Oct. 24, 2011).

The genome is an organism’s complete set of DNA. Genomes vary widely in size: the
smallest known genome for a free-living organism (a bacterium) contains about
600,000 DNA base pairs, while human and mouse genomes have some 3 billion.
Except for mature red blood cells, all human cells contain a complete genome.
From the Genome to the Proteome, HUMAN GENOME PROJECT SCIENCE, http://www.ornl.gov/
sci/techresources/Human_Genome/project/info.shtml (last visited Oct. 24, 2011).
19

President Obama Signs America Invents Act, Overhauling the Patent System to
Stimulate Economic Growth, and Announces New Steps to Help Entrepreneurs Create Jobs,
THE WHITE HOUSE (Sept. 16, 2011), http://www.whitehouse.gov/the-press-office/2011/09/16
/president-obama-signs-america-invents-act-overhauling-patent-system-stim (last visited Oct.
10, 2011).
20
21

1-1 CHISUM ON PATENTS §1.01 (LexisNexis 2011).

Compare Eric D. Zard, Patentability of Human Genetic Information: Exploring Ethical
Dilemmas Within the Patent Office and Biotechnology’s Clash with the Public Good, 6 U. ST.
THOMAS L.J. 486, 493 (2009) (establishing the concerns regarding gene patents), with The
Leahy-Smith America Invents Act, H.R. 1249, 120th Cong. (2011) (enacted), reprinted in
www.uspto.gov/aia_implementation/bills-112hr1249enr.pdf (failing to address the concerns
established by critics of gene patents).
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II. GENETICS 101: BASIC EDUCATIONAL FOUNDATION
A. Dissecting the Double Helix of Deoxyribonucleic Acid
An organism’s complete set of deoxyribonucleic acid (DNA)22 is known as its
genome.23 DNA is arranged in the nucleus of each cell within the human body.24
Each nucleus contains two sets of chromosomes, one set given by each parent, for a
total of forty-six chromosomes. 25 Each chromosome contains a single strand of
DNA.26 The DNA double helix is a linear arrangement of repeating nucleotides.27
Nucleotides are composed of one sugar, one phosphate, and a nitrogenous base.28 A
nucleotide can contain one of four nitrogenous bases: adenine (A), guanine (G),
cytosine (C), or thymine (T).29 These bases pair up with one another, A with T, and
C with G, to form base pairs.30 The order of these base pairs “determines the
information available for building and maintaining an organism, similar to the way
in which letters of the alphabet appear in a certain order to form words and
sentences.”31
A gene is “a specific sequence of nucleotides in DNA” found on a
chromosome.32 The specific sequence of nucleotides “determine[s] how, when, and
where the body makes each of the many thousands of different proteins required for

22

DNA is the hereditary material found in all multi-celled organisms. An Overview of the
Human Genome Project, NATIONAL HUMAN GENOME RESEARCH INSTITUTE, http://www.gen
ome.gov/12011238 (last visited Oct. 25, 2011).
23

From the Genome to the Proteome, supra note 18. Deoxyribonucleic acid (“DNA”) was
first identified by Friedrich Miescher, a Swiss chemist, in the late 1860s. Leslie A. Pray,
Discovery of DNA Structure and Function: Watson and Crick, NATURE EDUCATION,
http://www.nature.com/scitable/topicpage/discovery-of-dna-structure-and-function-watson397 (last visited Oct. 24, 2011). Friedrich Miescher identified what he termed a “nuclein”
inside the nuclei of a human white blood cell. Id. “The term ‘nuclein’ was later changed to
‘nucleic acid’ and eventually to ‘deoxyribonucleic acid,’ or ‘DNA.’” Id. In addition to
Miescher’s contributions, Phoebus Levene and Erwin Chargaff research uncovered the
primary chemical components of DNA, as well as how each chemical component joins with
one another. Id. In 1953, James Watson and Francis Crick discovered the three-dimensional
double helix structure of DNA. Id.
24

Handbook: Help Me Understand Genetics, GENETICS HOME REFERENCE 9, http://ghr
.nlm.nih.gov/handbook.pdf (last visited Feb. 18, 2013).
25

Id. at 15.

26

Chromosomes FAQs, HUMAN GENOME PROJECT INFORMATION, http://www.ornl.gov/sc
i/techresources/Human_Genome/posters/chromosome/faqs.shtml (last visited Nov. 24, 2011).
27

Id.

28

Id.

29

Handbook: Help Me Understand Genetics, supra note 24, at 9.

30

Handbook: Help Me Understand Genetics, supra note 24, at 9.

31

Handbook: Help Me Understand Genetics, supra note 24, at 9.

32

Gene, MERRIAM-WEBSTER ONLINE DICTIONARY, http://www.merriam-webster.com/dic
tionary/gene (last visited Oct. 24, 2011).
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life.”33 “Genes make up less than [two] percent of human DNA.”34 The remaining
DNA has important functions; however, those functions are still unknown.35 It is
speculated that those functions could “include regulating genes and maintaining the
chromosome structure.”36 When a nitrogenous base changes within the nucleotide of
a gene, disorders and diseases result.37 For example, “cystic fibrosis38 (chromosome
7) and sickle cell anemia39 (chromosome 11) are caused by base sequence changes in
a single gene.”40Common diseases, such as cancer and diabetes, have complex
causes that could be the result of base sequence changes on several genes
encompassing several chromosomes.41In 1990, a project called the Human Genome42
Project was orchestrated to learn more about the makeup of human DNA and genetic
material.43
B. The Human Genome Project
The Human Genome Project (“HGP”) was a collaborative, international research
project aimed at producing a complete map of the human genome.44 The project was
33

Chromosome FAQs, supra note 26.

34

Chromosome FAQs, supra note 26.

35

Chromosome FAQs, supra note 26.

36

Chromosome FAQs, supra note 26.

37

Chromosome FAQs, supra note 26.

38

Cystic Fibrosis, commonly referred to as CF, “is caused by a defective gene which
causes the body to produce abnormally thick and sticky fluid, called mucus,” that builds up in
the lungs and pancreas. Cystic Fibrosis, PUBMED HEALTH, http://www.ncbi.nlm.nih.gov/pub
medhealth/PMH0001167 (last visited Feb. 17, 2013). The collection of mucous in the
respiratory system and pancreas “results in life-threatening lung infections and serious
digestion problems.” Id. The average lifespan of individuals with CF is about thirty-seven.
Individuals with CF typically die due to lung complications. Id.
39

Sickle cell anemia is a genetic disease that results in an abnormal crescent or sickle
shaped red blood cell. Sickle Cell Anemia, PUBMED HEALTH, http://www.ncbi.nlm.nih.gov/pu
dmedhealth/PMH0001554/ (last visited Feb. 18, 2013). Normally, red blood cells are shaped
like a disc. Id. Individuals with sickle cell anemia have an abnormal type of hemoglobin
known as hemoglobin S. Id. Hemoglobin is a protein that carries oxygen that is located within
a red blood cell. Id. “Sickle cell disease is much more common in people of African and
Mediterranean descent.” Id.
40

Chromosome FAQs, supra note 26.

41

Chromosome FAQs, supra note 26.

42

An organism’s complete set of DNA is known as its genome. From the Genome to the
Proteome, supra note 18.
43
44

An Overview of the Human Genome Project, supra note 22.

An Overview of the Human Genome Project, supra note 22. The United States National
Institute of Health (NIH) and the Department of Energy funded the HGP. The Human Genome
Project: A New Reality, WELLCOME TRUST SANGER INSTITUTE, http://www.sanger.ac.uk/about/
history/hgp/ (last visited Feb. 18, 2013). Specifically the goals for HGP included the
following: (1) to identify the 20,000-25,000 genes in the human genome; (2) to determine the
sequences of the nitrogenous base pairs that make up the human DNA; (3) to store the
gathered information in a database; (4) “to improve tools for data analysis;” (5) “to transfer
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expected to take fifteen years, but was completed in 2003.45 The HGP decoded the
human genome in three ways.46 First, it determined the sequence of all the
nitrogenous bases that comprise DNA.47 Second, it produced maps of gene locations
and sections of chromosomes.48 Third, it produced linkage maps to track inherited
traits over generations.49 The full genetic sequence of the human genome was
completed in April 2003, which revealed about 20,500 human genes.50 Knowledge
regarding the make-up of DNA and the sequences that compose genes has and will
continue to lead to revolutionary mechanisms in research, technology, diagnoses,
treatments, and preventive measures in healthcare, and within medical fields.51

the related technologies to the private sector, and” (6) “to address the ethical, legal, and social
issues that arise from the project.” About Human Genome Project, HUMAN GENOME PROJECT
INFORMATION,
http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml
(last visited Oct. 25, 2011). While the HGP was being launched, John Sulston in the UK
began “mapping the genome of [a] nematode worm . . . .” The Human Genome Project: A
New Reality, supra note 44. Sulston approached the Wellcome Trust to form a new
partnership, at which time Wellcome suggested Sulston and his group get involved in the
HGP. Id. By the end of 1993, Sulston and his group of scientists began assisting in the quest
of the HGP. Id.
45

About Human Genome Project, supra note 44.

46

An Overview of the Human Genome Project, supra note 22. Researchers used the
hierarchal shotgun method to accurately sequence the human genome. The Human Genome
Project: A New Reality, supra note 44. “Researchers agreed that this was the best way to
achieve the Human Genome Project’s target of 95% coverage of the human genome by 2005.”
The Human Genome Project: A New Reality, supra note 44. There are two main strategies
when it comes to sequencing a genome. The first method is the hierarchical shotgun method
as implemented by the HGP. The Human Genome Project: A New Reality, supra note 44.
The second method is the shotgun sequencing method:
The advantage to the hierarchical approach is sequencers are less likely to make
mistakes when assembling the shotgun fragments into contigs as long as full
chromosomes. The reason is that the chromosomal location for each BAC is known,
and there are fewer random pieces to assemble. The disadvantage to this method is
time and expense. The shotgun method is faster and less expensive, but it is more
prone to errors due to incorrect assembly of finished sequence.
The Human Genome Project: A New Reality, supra note 44. The size and complexity of the
genome is what determines which sequencing method is better to use. The Human Genome
Project: A New Reality, supra note 44.
47

An Overview of the Human Genome Project, supra note 22.

48

An Overview of the Human Genome Project, supra note 22.

49

An Overview of the Human Genome Project, supra note 22.

50

An Overview of the Human Genome Project, supra note 22. The number of genes found
by the HGP was significantly less than what had been estimated by researchers. An Overview
of the Human Genome Project, supra note 22. Researchers believed that between 50,000 and
140,000 genes existed within the human genome. An Overview of the Human Genome
Project, supra note 22.
51

An Overview of the Human Genome Project, supra note 22.
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C. The HabMap Project
Concurrently with the HGP, the International HapMap52 Consortium launched
the International HapMap Project (HapMap Project) in 2002.53 The HapMap Project
was “aimed at speeding [up] the discovery of genes related to common illnesses [and
diseases].”54 Uncovering the genetic variations that lead to common diseases such as
Alzheimer’s, cancer, and diabetes is difficult because these disorders are caused by
variations in multiple genes versus a single variation within one gene.55 The
variations in the nitrogenous bases within DNA are called single nucleotide
polymorphisms (SNPs).56 A set of SNPs found on the same chromosome is known
as a haplotype.57 The HapMap Project produced a public database of the SNPs and
haplotypes that the project uncovered in order to share the results internationally
with other scientists.58 Scientists use SNPs and haplotypes to compare the genetic
differences between healthy individuals and individuals with common diseases.59 By
52
“HapMap stands for ‘Haplotype Map.’” You and the $1000 Genome Part II: The
International HapMap Project, THE GENETIC GENEALOGIST, http://www.thegeneticgenealo
gist.com/2007/05/24/you-and-the-1000-genome-%E2%80%93-part-ii-the-international-hapma
p-project/ (last visited Nov. 7, 2011).
53

David Secko, Phase I of HapMap Complete, THE SCIENTIST: MAGAZINE OF HEALTH
SCIENCES, http://classic.the-scientist.com/news/20051026/01/ (last visited Oct. 24, 2011).
54

International Consortium Launches Genetic Variation Mapping Project: HapMap will
Help Identify Genetic Contributions to Common Diseases, supra note 18. The HapMap
Program is a catalogue of SNPs “that maps the natural organization of the human genome in
blocks called haplotypes.” David Secko, supra note 53.
During the study, researchers took 296 DNA samples from four populations in
Nigeria, Tokyo, Beijing, and Utah, aiming to genotype one SNP for every 5kb of
genome. They characterized over one million SNPs, verified the low haplotype
diversity in the above populations, and created a fine-scale genetic map of 21, 617
recombination hotspots.
Id. The second phase of the HapMap Project “analyzed an additional 2.1 million[] SNPs.” Id.
55

International Consortium Launches Genetic Variation Mapping Project: HapMap will
Help Identify Genetic Contributions to Common Diseases, supra note 18.
56

International Consortium Launches Genetic Variation Mapping Project: HapMap will
Help Identify Genetic Contributions to Common Diseases, supra note 18.
57
Haplotype, NATIONAL HUMAN GENOME RESEARCH INSTITUTE, http://www.genome.gov
/Glossary/index.cfm?id=99 (last visited Oct. 25, 2011). A haplotype is “a set of DNA
variations, or polymorphisms, that tend to be inherited together.” Id. “A haplotype can refer to
a combination of alleles or to a set of single nucleotide polymorphisms (SNPs) found on the
same chromosome. Information about haplotypes is being collected by the International
HapMap Project and is used to investigate the influence of genes on disease.” Id.
58
59

Secko, supra note 53.

International Consortium Launches Genetic Variation Mapping Project: HapMap will
Help Identify Genetic Contributions to Common Diseases, supra note 18. This method of
research is known as an association study. International Consortium Launches Genetic
Variation Mapping Project: HapMap will Help Identify Genetic Contributions to Common
Diseases, supra note 18. “If the association study finds a certain haplotype more often in the
people with the disease, researchers would then zero in on that genomic region in their search
for the specific genetic variant. The tag SNPs would serve as signposts indicating that a
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looking at the differences in genetic variations between individuals with a disease
and healthy individuals, researchers can uncover the specific genetic sequences
responsible for particular illnesses and diseases, and in turn, work towards
uncovering treatments and eventually cures.60
D. The Future of Genetic Research
The HGP and the HapMap Project have greatly amplified genetic studies and
research around the world, which has resulted in an increase of patent applications.61
Within the United States alone, 3,000 to 5,000 patents on human genes have been
issued, as well as around 47,000 patents for inventions related to genetic material.62
While patenting is widely accepted around the world, “many countries limit the
scope of gene patents as a way to minimize the negative impact on health care costs
and on the free flow of information in research.”63
The United States had the opportunity to limit the scope of gene patents when the
government issued the AIA in September 2011; however, no measures to regulate
gene patents were outlined in the new law.64 Gene patents should not be categorized
as utility patents under the AIA. Instead gene patents should be categorized in a
separate patent category, specifically designed to promote scientific research and
collaboration.This in turn will advance scientific breakthroughs in health and
science, resulting in positive diagnoses and treatments, thus saving millions of lives.
III. THE HISTORY OF THE U.S. PATENT SYSTEM AND THE EFFECT OF THE LEAHYSMITH AMERICA INVENTS ACT
A. Legislative History of the United States Patent System
Under Article I, Section 8 of the United States Constitution, Congress has the
power “to promote the Progress of Science and useful Arts, by securing for limited
Times to Authors and Investors the exclusive Right to their respective Writings and
genetic variant involved in the disease may lie nearby.” International Consortium Launches
Genetic Variation Mapping Project: HapMap will Help Identify Genetic Contributions to
Common Diseases, supra note 18. Research has proven “that any two people are 99.9 percent
identical at the genetic level, the 0.1 percent difference is important because it helps explain
why one person is more susceptible to a specific disease – say diabetes – then someone who is
less susceptible.” International Consortium Launches Genetic Variation Mapping Project:
HapMap will Help Identify Genetic Contributions to Common Diseases, supra note 18.
60
International Consortium Launches Genetic Variation Mapping Project: HapMap will
Help Identify Genetic Contributions to Common Diseases, supra note 18.
61
“A patent for an invention is the grant of a property right to the inventor, issued by the
United States Patent and Trademark Office.” General Information Concerning Patents,
UNITED STATES PATENT AND TRADEMARK OFFICE, http://www.uspto.gov/patents/resources/gen
eral_info_concerning_patents.jsp (last visited Nov. 26, 2011).
62

Robert Cook-Deegan, From Birth to Death and Bench to Clinic: The Hastings Center
Bioethics Briefing Book for Journalists, Policy Makers, and Campaigns, 69, http://www.theha
stingscenter.org/Publications/BriefingBook/Detail.aspx?id=2174 (last visited Oct. 25, 2011),
cited in Zard, supra note 21.
63
64

Cook-Deegan, supra note 62.

The Leahy-Smith America Invents Act, H.R. 1249, 120th Cong. (2011) (enacted),
reprinted in www.uspto.gov/aia_implementation/bills-112hr1249enr.pdf .
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Discoveries.”65 The first United States Patent Act was established in 1790.66 The
statute remained unchanged until 1952.67 The Act of 1952 provided, “[w]hoever
invents or discovers any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof, may obtain a
patent therefore, subject to the conditions and requirements of this title.”68 A
patentable invention or discovery must be (1) novel, (2) nonobvious, (3) adequately
described or enabled, and (4) claimed by the inventor in clear and definite terms.69
The United States Patent and Trademark Office (“USPTO”)70 classifies patents into
three categories: (1) utility patents, (2) design patents, and (3) plant patents.71 Gene
patents are categorized under utility patents.72
65

U.S. CONST. art. I, § 8, cited in Zard, supra note 21, at 490.

66

1-1 Chisum on Patents §1.01 (LexisNexis 2011). The Patent Act of 1790 “covered ‘any
useful art, manufacture, engine, machine, or device, or any improvement therein.’” Id. The
language was later changed “to read ‘any art, machine, manufacture, or composition of matter,
or any new and useful improvement [therein].’” Id.
67
Id. “[T]he Patent Act of 1952 changed the language from ‘art’ to mean ‘process,’ and
defined ‘process’ as meaning ‘process, art or method.’ The 1952 Act also defined, particularly
redundantly, ‘invention’ as ‘invention or discovery.’” Id.
68

35 U.S.C.S. § 101 (LexisNexis 2011), cited in Zard, supra note 21, at 487, 490.

69

Patents, UNITED STATES PATENT AND TRADEMARK OFFICE, http://www.uspto.gov/inve
ntors/patents.jsp#heading-5 (last visited Nov. 9, 2011).
70
The United States Patent and Trademark Office (USPTO) is a government agency
within the United States Department of Commerce. Zard, supra note 21. “[T]he USPTO
fulfills the mandate of Article I, Section 8, Clause 8, of the Constitution that the Executive
branch "promote the progress of science and the useful arts by securing for limited times to
inventors the exclusive right to their respective discoveries." The USPTO: Who We Are, THE
UNITED STATES PATENT AND TRADEMARK OFFICE, http://www.uspto.gov/about/index.jsp (last
visited Jan. 19, 2012). Trademarks are registered by the USPTO based on the Commerce
Clause. Id. Under the USPTO, the industry in America has flourished. Id. “The strength and
vitality of the U.S. economy depends directly on effective mechanisms that protect new ideas
and investments in innovation and creativity.” Id. In addition to registering trademarks and
patents, “[t]he USPTO advises the President of the United States, the Secretary of Commerce,
and U.S. Government agencies on intellectual property (IP) policy, protection, and
enforcement; and promotes the stronger and more effective IP protection around the world.”
Id. The USPTO headquarters is located in Alexandria, Virginia. Id. The office is comprised of
more than 8,900 employees including attorneys, analysts, engineers, scientists, and computer
specialists. Id.
71

General Information Concerning Patents, supra note 61; see also Zard, supra note 21.

72
General Information Concerning Patents, supra note 61. Utility patents are “[i]ssued
for the invention of a new and useful process, machine, manufacture, or composition of
matter, or a new and useful improvement thereof, it generally permits its owner to exclude
others from making, using, or selling the invention for a period of up to twenty years from the
date of patent application filing, subject to the payment of maintenance fees. Approximately
90% of the patent documents issued by the PTO in recent years have been utility patents, also
referred to as ‘patents for inventions.’” Types of Patents, UNITED STATES PATENT AND TRADEMARK OFFICE, http://www.uspto.gov/web/offices/ac/ido/oeip/taf/patdesc.htm (last visited Nov.
26, 2011). Design patents are issued for original, new, and ornamental design. Id. Design
patents “permit[] its owner to exclude others from making, using, or selling the design for a
period of fourteen years from the date of patent grant.” Id. Plant patents are issued for new,
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In general, products from nature are not patentable; however, the USPTO permits
genes, and even DNA, to be patentable subject matter.73 The USPTO defines “gene
patents” to include “full-length protein encoding gene, a gene fragment, a regulatory
region, a cDNA molecule, or a genomic region of unknown function.”74 For DNA to
be a patentable subject matter, the USPTO requires that it be “isolated, purified, or
modified to produce a unique form not found in nature” that has a specific
application or use.75 Patent protection for utility patents lasts for twenty years from
the date of the first application.76 To obtain a gene patent inventors are required to
“(1) identify novel genetic sequences, (2) specify the sequence’s product, (3) specify
how the product functions in nature (i.e. its use), and (4) enable one skilled in the
field to use the sequence for that purpose.”77 While the USPTO appears to have a
system in place to regulate gene patents, legal issues continue to exist that question
whether genetic material is patentable subject matter within the scope of 35 U.S.C §
101.78
B. The Common Law Approach to Gene Patents
Much debate has arisen from legislative and judicial recognition of gene patents
as patentable subject matter within the scope of 35 U.S.C. § 101. Arguments, both
legal and ethical, concerning gene patents have been vocalized since 1980 with

distinct asexually reproduced plants “including cultivated sports, mutants, hybrids, and newly
found seedlings, other than a tuber propagated plant or a plant found in an uncultivated state.”
Id. Asexually reproduced plants reproduce via fragmentation or division. Asexual
Reproduction, UCMP BERKLEY, http://www.ucmp.berkeley.edu/ glossary/gloss6/asexual.html
(last visited Jan. 19, 2012). New plants grow by a “separation of parts [from] the original
plant.” Id. In other words, “an offspring is created by the breakup of a single part of the plant.”
Id. In essence, a plant clones itself through the process of asexual reproduction, which in some
ecosystems is advantageous if genetic material through pollen reproduction is not readily
available. Id. A plant patent is granted to cover the entire plant. General Information
Concerning Patents, supra note 61. The plant patent term lasts twenty years from the date on
which the application was filed in the U.S. General Information Concerning Patents, supra
note 61. Both utility and plant patents are protected for terms of twenty years, while the design
patent is only protected for a fourteen-year term. General Information Concerning Patents,
supra note 61.
73
Genetics and Patenting, HUMAN GENOME PROJECT INFORMATION, http://www.ornl.gov/s
ci/techresources/Human_Genome/elsi/patents.shtml#1 (last visited Nov. 9, 2011).
74

Zard, supra note 21 (citing Gregory C. Ellis, Emerging Biotechnologies Demand
Defeat of Proposed Legislation that Attempts to Ban Gene Patents, 15 RICH. J.L. & TECH. 1, 7
(2008)).
75

Genetics and Patenting, supra note 73.

76

Patents, supra note 69.

77

Zard, supra note 21, at 492 (citing Genetics and Patenting, supra note 73); see also
Michele Westhoff, Gene Patents: Ethical Dilemmas and Possible Solutions, 20 HEALTH L. 1,
3 (2008).
78

See Diamond v. Chakrabarty, 447 U.S. 303 (1980).
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Diamond v. Chakrabarty, and more recently in July, 2011 and again in August, 2012
with the Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office.79
1. The Impact of Diamond v. Chakrabarty
In Diamond v. Chakrabarty, the Supreme Court held that “[a] live, human-made
micro-organism [was] patentable subject matter” pursuant to 35 U.S.C. § 101.80 In
Chakrabarty, the defendant Chakrabarty, a microbiologist, filed an application to
patent his “invention of ‘a bacterium from the genus pseudomonas.’”81 The “humanmade, genetically engineered bacterium” designed by Chakrabarty was “capable of
breaking down multiple components of crude oil.”82 At that time, the discovery was
believed to have made a substantial impact in the treatments used to clean up oil
spills because no “naturally occurring bacteria” possesses such capabilities.83
Chakrabarty applied for three different patent claims.84 The first claim was a
process claim “for the method of producing the bacteria.”85 The second claim was
“for an inoculum86 comprised of a carrier material floating on water,” and the
invented bacteria.87 The third claim was solely for the invented bacteria.88 The patent
79

Chakrabarty, 447 U.S. at 303 (1980) (holding that a man-made microorganism was patentable under 35 U.S.C.S. § 101); Ass’n for Molecular Pathology v. U.S. Patent & Trademark
Office, 2011 U.S. App. LEXIS 15649 (Fed. Cir. July 31, 2011) (holding that isolated DNA
sequences were patentable subject matter); Ass’n for Molecular Pathology v. U.S. Patent &
Trademark Office, 689 F.3d 1303 (2012).
80

Chakrabarty, 447 U.S. 303 (1980).

81

Id. at 305. The created bacteria contained “two stable energy generating plasmids, each
said plasmids provid[ed] a separate hydrocarbon degradative pathway.” Id. “Plasmids are
hereditary units physically separate from the chromosomes of the cell.” Id. at n.1.
Chakrabarty discovered the plasmids control of the oil degradation abilities of certain bacteria
through previous research with an associate. Id. Specifically, Chakrabarty and his associate
found plasmids that were capable of degrading two components of oil, camphor and octane.
Id. In the present case, “Chakrabarty discovered a process by which four different plasmids,
capable of degrading four different oil components, could be transferred to and maintained
stably in a single Pseudomonas bacterium, which itself has no capacity for degrading oil.” Id.
82

Id. at 305.

83

Id. “At present, biological control of oil spills requires the use of a mixture of naturally
occurring bacteria, each capable of degrading one component of the oil complex. In this way,
oil is decomposed into simpler substances which can serve as food for aquatic life. However,
for various reasons, only a portion of any such mixed culture survives to attack the oil spill.
By breaking down multiple components of oil, Chakrabarty’s micro-organism promises more
efficient and rapid oil-spill control.” Id. at n.2.
84

Id. at 305.

85

Id.

86

Inoculums are “cells used in an inoculation, such as cells to start a culture.” Inoculum,
BIOLOGY-ONLINE, http://www.biology-online.org/dictionary/Inoculum (last visited Jan. 17,
2012). In terms of microbiology, inoculation is “the act of introducing [a] microorganism or
[a] suspension of microorganisms (e.g. bacteria) into a culture medium. Id.
87

Chakrabarty, 447 U.S. at 306 (1980).

88

Id.
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examiner approved the first two claims, however, the third claim was rejected for
two reasons.89 First, the patent examiner argued that the “microorganism [was a]
‘product[] of nature.’”90 Secondly, the patent examiner argued since the
“microorganism [was a] ‘product[] of nature,’” it qualified as a living entity, and
therefore was not patentable under 35 U.S.C. § 101.91 Chakrabarty appealed to the
Patent Office Board of Appeals, which was later granted certiorari by the Supreme
Court.92
The main question before the Court was whether the microorganism could be
classified as a “manufactured” entity or a “composition of matter’” within the scope
of 35 U.S.C. § 101.93 The Court defined “manufacture” as “the production of articles
for use from raw or prepared materials by giving to these materials new forms,
qualities, properties, or combinations, whether by hand-labor or by machinery.”94
“Composition of matter” was defined to include “all compositions of two or more
substances and…all composite articles, whether they be the results of chemical
union, or of mechanical mixture, or whether they be gases, fluids, powders, or
solids.”95 The Court did not find “manufacture” and “composition of matter” to be
ambiguous terms.96 Instead, the Court reasoned that Congress plainly used expansive
language to provide a wide scope of patentable objects within the U.S. patent
system.97 The Court argued the broad terms “fulfill[ed] the [C]onstitutional and
statutory goal of promoting ‘the Progress of Science and the useful Arts’ with all the
means for the social and economic benefits envisioned by [Thomas] Jefferson.”98
89

Id.

90

Id.

91

Id.

92

Id. at 306-07. The Patent Office Board of Appeals found that 35 U.S.C. § 101 did not
protect living entities, such as the one created by Chakrabarty. Id. at 306. The Court of
Customs and Patent Appeals then reversed a prior decision it had made “in In re Bergy, 563
F.2d 1031, 1038 (1977), which held that ‘the fact that microorganisms . . . are alive . . . [is]
without legal significance’ for purposes of patent law.” Id. “Bergy involved a patent
application for a pure culture of the micro-organism Streptomyces vellosus found to be useful
in the production of lincomycin, an antibiotic.” Id. at n.4. The Supreme Court granted
certiorari, and remanded Bergy “for further consideration in light of Parker v. Flook, 437 U.S.
584.” Id. at 306. After, the Court of Customs and Patent Appeals vacated its decision in
Chakrabarty and consolidated the case with Bergy for reconsideration, affirmed the earlier
judgments. Id. The Supreme Court granted certiorari for both cases, however, Bergy was
dismissed as moot, leaving only Chakrabarty. Id. at 307.
93

Id. at 307.

94

Chakrabarty, 447 U.S. at 308 (citing American Fruit Growers, Inc. v. Brogdex Co., 283
U.S. 1 (1931)).
95

Chakrabarty, 447 U.S. at 308 (citing Shell Development Co. v. Watson, 149 F.Supp,
279, 280 (D.C. 1957) (citing 1 A. Deller, Walker on Patents § 14, p. 55 (1st ed. 1937))).
96

Chakrabarty, 447 U.S. at 315.

97

Id. at 308.

98

Id at 315. Thomas Jefferson was a major contributor to the Patent Act of 1793. Id at
308. Jefferson defined patentable subject matter as “any new and useful art, machine,
manufacture, or composition of matter, or any new or useful improvement [thereof].”
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While it appeared to the Court on the surface that Congress provided a wide
scope in regards to the definition of “manufacture” and “composition of matter,”
limitations exist that categorize certain entities as non-patentable objects.99 Abstract
ideas, the laws of nature (i.e. gravity), and physical phenomena are three categories
that cannot be patented.100 While an individual cannot patent the discovery of a new
plant or the discovery of a new mineral on Earth, the Court found that the
microorganism created by Chakrabarty could not be found in nature, and therefore,
fit within the scope of “manufacture” and “composition of matter” under 35 U.S.C. §
101 as patentable subject matter.101
The Supreme Court’s decision in Chakrabarty initiated a rush for gene patents
within the U.S. patent system by widening the scope of patentable subject matter to
allow all substances not found in nature to be patentable under 35 U.S.C. § 101.
Since Chakrabarty, patents have been permitted for whole genes, segments of genes,
and even fragments of DNA.102 While the USPTO has attempted to establish
guidelines for gene patents since the Court’s holding in Chakrabarty, issues still
arise today that question the very foundation of whether genetic information is
patentable as seen in the Ass’n for Molecular Pathology v. U.S. Patent & Trademark
Office.103
2. The Ongoing Debate of the Ass’n for Molecular Pathology v. U.S. Patent &
Trademark Office
In the Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, the
U.S. Court of Appeals for the Federal Circuit reversed the decision of the U.S.
District Court for the Southern District of New York, holding that isolated DNA is
patentable subject matter.104 Mutations in BRCA1 and BRCA2 genes have been
linked to an increased risk of breast and ovarian cancer development in women.105
Women in the United States have a twelve to thirteen percent chance of developing
breast cancer within a lifetime.106 In the United States, women that have either a
BRCA1 or BRCA2 mutation have a fifty to eighty percent chance of developing
Chakrabarty, 447 U.S. at 308 (citing Act of Feb. 21, 1793, § 1, 1 Stat. 319). The 1793 Act
“embodied Jefferson’s philosophy that ‘ingenuity should receive a liberal encouragement.’”
Chakrabarty, 447 U.S. at 308 (citing 5 WRITINGS OF THOMAS JEFFERSON 75-76 (Washington
ed. 1871)).
99

Chakrabarty, 447 U.S. at 309.

100

Id.

101

Id. at 309-10.

102

Genetics and Patenting, supra note 73.

103

Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 2010-1406,
2011 U.S. App. LEXIS 15649 at *54 (Fed. Cir. July 31, 2011).
104

Id. The non-patentability of the isolated DNA segments were not the only issues raised
before the court. Id. at *8. The plaintiffs “sought a declaration that fifteen claims from the
seven patents assigned to Myriad [were] drawn to patent ineligible subject matter under 35
U.S.C. § 101.” Id.
105

Id. at *17.

106

Id.
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breast cancer and a twenty to fifty percent chance of developing ovarian cancer.107
Diagnostic testing provides women with information regarding their risk for
developing hereditary breast and/or ovarian cancers, which in turn allows women the
option to take preventative measures to avoid cancer development.108 Diagnostic
results can also assist in developing proper chemotherapy treatments because some
treatments are tailored to effectively treat BRCA1 and BRCA2 related cancers.109
In the Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, the
defendants, Myriad Genetics, Inc. (“Myriad”), discovered that BRCA1 and BRCA2
mutations had a relationship with cancer development.110 Using DNA samples from
families afflicted with inherited ovarian cancer and breast cancer, the researchers at
Myriad were able to identify individual family members with a particular DNA
sequence marker, which facilitated researchers to map the location of the BRCA1
and BRCA2 genes within the human genome.111 Once the location of the two genes
had been mapped, researchers isolated the exact nucleotide sequences, which
allowed Myriad to provide BRCA1 and BRCA2 diagnostic testing for women with
breast cancer and ovarian cancer.112
Myriad filed its first patent application for the isolated BRCA1 DNA and the
associated diagnostic methods in August 1994, and the patent, ‘472 patent, was
issued in December 1997.113 Myriad filed its patent application for the isolated
BRCA2 DNA and the associated diagnostic methods in December of 1995, and the
patent, ‘492 patent, was issued in November 1998.114 The district court found that
the isolated DNA molecules of BRCA1 and BRCA2, were non-patentable subject
matter because the “isolated DNAs [were] not ‘markedly different’ from native

107

Id.

108

Id.

109

Id. at *18.

110

Id.

111

Id.

112

Id.

113

Id.

114

Id. at *18-19. Even though Myriad had patents for both the isolated BRCA1 and
BRCA1 DNA and subsequent diagnostic methods, Myriad was not the only entity to
implement clinical testing with the two strands of DNA. Id. at *19. In 1996, the University of
Pennsylvania’s Genetic Diagnostic Laboratory, which was co-directed by some of the
plaintiffs, began providing diagnostic services to women for BRCA1 and BRCA2. Id. The
Genetic Diagnostic Laboratory was forced to stop providing services based on accusations by
Myriad. Id. Around the same time, Myriad “initiated several other patent infringement suits
against entities providing clinical BRCA testing. Id. at *22. Dr. Kazazian was one of the
researchers at the Genetic Diagnostic Laboratory at the University of Pennsylvania. Id. at *19.
Dr. Kazazian, like other researchers, believed that the patents held by Myriad should be found
invalid so that he and other researchers could resume testing with BRCA. Id. at *23. After the
plaintiffs filed suit, Myriad attempted to have the case dismissed alleging that the plaintiffs
lacked standing. Id. The district court disagreed, and found that the plaintiffs had established
standing with the “all circumstances” test. Id.
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DNAs,” and instead were properly categorized as “products of nature” within the
exceptions of 35 U.S.C. § 101 as described in Chakrabarty.115
To determine whether the BRCA1 and BRCA2 isolated DNA molecules were
patentable subject matter, the court of appeals analyzed the Supreme Court’s
decisions in Chakrabarty and Funk Brothers.116 Both cases involved patents
regarding discovered bacteria, however, unlike Chakrabarty, the bacteria in Funk
Brothers was non-patentable because the non-inhibition characteristic that was
“newly discovered” was not “markedly different” from the bacteria found in
nature.117 Therefore, the distinction between a product of nature and a patentable
human-made discovery in correlation with 35 U.S.C. § 101 depends on “the claimed
composition’s identity compared with what exists in nature.”118
The court of appeals held that the BRCA1 and BRCA2 isolated sequences were
patentable subject matter because the discovered sequences were different from the
natural form, and, therefore, did not fall within the exceptions of 35 U.S.C. § 101.119
The court came to this conclusion based on the science and techniques used by the
Myriad researchers.120 Isolated DNA “is a free-standing portion of a native DNA
molecule.”121 Isolated DNA has been synthesized to consist of a fraction of the
naturally occurring DNA molecule.122 DNA that has been synthesized or cleaved
from native DNA has a “distinctive chemical identity from that possessed by native
DNA.”123 In their isolated states, BRCA1 and BRCA2 “are not the same molecules
115

Id. at *26. Myriad argued that the district court came to the incorrect conclusion by “(1)
misreading Supreme Court precedent as excluding from patent eligibility all ‘products of
nature’ unless ‘markedly different’ from naturally occurring ones; and (2) incorrectly focusing
not on the differences between isolated and native DNAs, but on one similarity: their
informational content.” Id. at *47-48. Myriad argued that “an isolated DNA molecule is patent
eligible because it is, as claimed, ‘a nonnaturally occurring composition of matter’ with ‘a
distinctive name, character and use.’” Id. at *48. Myriad outlined that “isolated DNA does not
exist in nature, and isolated DNAs, unlike native DNAs [the natural form], can be used as
primers and probes for diagnosing cancer.” Id. Myriad asserted that the “products of nature”
exception not only wasn’t possible to apply because at some level every composition on Earth
is comprised of natural materials, but that such a decision would go against the court’s
precedents. Id. The plaintiffs responded by arguing that the Supreme Court’s precedents
establish that “a product of nature is not patent eligible even if, as claimed, it has undergone
some highly useful change from its natural form.” Id. Plaintiffs asserted that the isolated
DNAs were not markedly different from its natural form, and in order to assert a composition
as patent eligible, the composition must “have a distinctive name, character, and use, making
it ‘markedly different’ from the natural product.” Id. at *49.
116

Id. at *51.

117

Id. at *53.

118

Id. at *54.

119

Id.

120

Id. at *56.

121

Id. at *55.

122

Id.

123

Id. at *56. “[T]he BRCAI gene in its native state resides on chromosome 17, a DNA
molecule of around eighty million nucleotides.” Id. at *55. “[The] BRCA2 in its native state is
located on chromosome 13, a DNA of approximately 114 million nucleotides. In contrast,
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as DNA as it exists in the body.”124 In other words BRCA1 and BRCA2 are different
from the DNA found in nature.125 The district court used a “categorical rule” that
excluded isolated genes from patent eligibility, which the court of appeals
rejected.126
In addition to holding the BRCA1 and BRCA2 isolated sequences as patentable
subject matter under 35 U.S.C. § 101 based on the test provided by Chakrabarty and
Funk Brothers, the court of appeals also looked to the “longstanding practice” of the
USPTO and the Supreme Court.127 The USPTO has issued patents for DNA
molecules for almost thirty years beginning in the 1980s.128 It has been “estimated
that the [US]PTO has issued 2,645 patents claiming ‘isolated DNA’” since 1980.129
In addition, about 40,000 DNA-related patents have been issued since 2005, twenty
percent of which were comprised of gene patents.130 Based on these statistics, it is
no wonder that the court of appeals’ decision was applauded by the biotechnology
industry.131 As stated by Gerald J. Flattmann Jr., a patent attorney for Paul Hastings
in New York City, “It [the court of appeals] adhered to the policy the Patent Office
has pursued since the early ‘80s, when the biotech industry was born. Isolated gene
patents are the cornerstones of the biotechnology industry.” 132
In his New York Times article Ruling Upholds Gene Patent In Cancer Test,
Andrew Pollack commented that the Ass’n for Molecular Pathology might reach the
Supreme Court for further ruling.133 The executive director of the Public Patent
Foundation, Daniel B. Ravicher, who helped file the lawsuit, “called the decision a
partial victory for the plaintiffs[,] [n]oting that one judge dissented on the gene
patents.”134 Ravicher also commented “the plaintiffs were considering either asking

isolated BRCA1 and BRCA2, with introns, each consist of just 80,000 or so nucleotides. And
without introns, BRCA2 shrinks to just 10,200 or so nucleotides and BRCA1 to just around
5,000 nucleotides.” Id. An intron is “[p]art of a gene that is initially transcribed into the
primary RNA transcript but then removed from it when the exon sequences on either side of it
are spliced together.” Intron, MEDICINENET.COM, http://www.medterms.com/script/main/art.a
sp?articlekey=4026 (last visited Jan. 18, 2012). An intron is also known as an intervening
sequence. Id.
124

Ass’n Molecular Pathology, 2011 U.S. App. LEXIS 15649 at *56.

125

Id.

126

Id. at *60.

127

Id. at *64.

128

Id. at *65.

129

Id.

130

Id.

131
Andrew Pollack, Ruling Upholds Gene Patent in Cancer Test, N.Y. TIMES, July 29,
2011, http://www.nytimes.com/2011/07/30/business/gene-patent-in-cancer-test-upheld-by-app
eals-panel.html?_r=1 (last visited Jan. 18, 2012).
132

Id.

133

Id.

134

Id.
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the entire appellate court to rehear the gene patenting aspects of the case or
appealing to the Supreme Court.”135
A petition of certiorari was filed from the July 29, 2011 court of appeals opinion,
in which the Supreme Court of the United States granted the petition, vacated the
decision, and remanded the case back to the court of appeals to be reconsidered in
the light of the Supreme Court’s decision in Mayo Collaborative Services v.
Prometheus Inc. (“Mayo”).136 The Supreme Court’s decision in Mayo “tightened
rules on medical-testing patents.”137 Specifically, the court “invalidated a pair of
‘method’ patents that claimed a process for setting dosages.”138 In the remanded
appeal, the court of appeals made a decision, which decided the issues on the
original appeal and evaluated the effect of Mayo on the original issues.139 On
remand, the court of appeals reversed the district court’s holding “that Myriad’s
composition claims to ‘isolated’ DNA molecules cover patent-ineligible products of
nature under § 101 because each of the claimed molecules represents a nonnaturally
occurring composition of matter.”140 Shortly after the court of appeals remanded
decision, the Supreme Court granted certiorari to establish whether human genes are
patentable subject matter.141
While Chakrabarty and the Ass’n for Molecular Pathology establish the
constitutional concerns regarding gene patents that the judicial system has so far
overturned, society has become increasingly split in its opinions of whether gene
patents should be permissible within the U.S. patent system.
135

Id.

136

Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 689 F.3d 1303,
1308 (Fed. Cir. Aug. 16, 2012).
137

Brent Kendall, Court to Decide Whether Genes Can Be Patented, WALL ST. J., July 20,
2012, at A3.
138
Id. “Judge Kimberly Moore, who penned a concurring opinion for the Federal Circuit
last year, wrote that the Myriad patents ‘raise substantial moral and ethical issues related to
awarding a property right to isolated portions of human DNA-the very thing that makes us
humans, and not chimpanzees.’ But she also said that the U.S. Patent and Trademark Office
has allowed patents on the DNA sequences for decades and that disturbing the industries longheld expectations risked impeding innovation.” Id.
139

Ass’n Molecular Pathology, 689 F.3d at 1308.

140

Id. at 1308-09. The court “also reversed the district court’s decision that Myriad’s
method claim to screening potential cancer therapeutics via changes in cell growth rates of
transformed cells is directed to a patent-ineligible scientific principle.” Id. Lastly, the court
affirmed the district court’s decision that the claims that “comparing” and “analyzing”
procedures for DNA sequences were patent ineligible because there were no transformative
steps. Id.
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Id. at 1308. On June 13, 2013, the Supreme Court of the United States unanimously
established that human genes may not be patented. Adam Liptak, Justices, 9-0, Bar Patenting
Human Genes, N.Y. TIMES, June 13, 2013, http://www.nytimes.com/2013/06/14/us/supremecourt-rules-human-genes-may-not-be-patented.html?_r=0 (last visited June 23, 2013). Justice
Clarence Thomas wrote for the court that “‘Myriad did not create anything…[t]o be sure, it
found an important and useful gene, but separating the gene from its surrounding genetic
material is not an act of invention.’” Id. This ruling “drew a sharp distinction between DNA
that appears in nature and synthetic DNA created in the laboratory.” Id.
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3. Society’s Split on Gene Patents
Since the 1980s with the Supreme Court’s holding in Chakrabarty, a split has
developed within society’s view regarding the patentability of genetic material.
Proponents argue that gene patents (1) reward researchers for their work and supply
monetary rewards to further their research, (2) “provide a monopoly to []
inventor[s]” in turn “prohibiting competitors from making, using, or selling []
patented discover[ies],” (3) prevent “wasteful duplications,” (4) force science to
reach “into new, unexplored areas,” and (5) reduce innovative secrecy and promote
communication between researchers.142 Opponents argue that gene patents (1)
impede on scientific research, (2) allow researchers to patent a part of nature, and (3)
allow monopolies.143 The themes argued by both sides of the debate can be
categorized into three sections: (1) the issues surrounding the creation of
monopolies, (2) the issues concerning the affects on scientific research, and (3) the
issues concerning patenting a part of “nature.”
i. Monopolies
Proponents of patenting genetic material argue that gene patents allow
researchers to monopolize their discoveries, which provides monetary and property
rewards.144 “Patents facilitate genetic research by encouraging investment in what
would otherwise be a risky financial investment.”145 The biotechnology industry, as
a whole, is a strong proponent for gene patents because a large portion of profit
comes from “intellectual and financial investments,” which in turn facilitate
research.146 Individuals challenging gene patents maintain that while monopolies
may be an asset to large biotechnological corporations, monopolies hurt smaller
corporations.147 Proponents for gene patents, however, disagree and argue that small
biotechnological corporations gain the same benefits as larger biotechnological
corporations.148 Regardless of size, if gene patents are barred, corporations that do
not have the sources to fund research will lose the ability to attract investors,
ultimately resulting in delays in research or completely preventing research from
occurring.149
While monopolies created by gene patents arguably assist in funding future
research, opponents argue that monopolies raise the cost of diagnostic testing that
could be reduced if biotechnological companies did not hold monopolies over their
patents.150 For example, Myriad Genetics, Inc. holds the patents for both BRCA1
142
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and BRCA2 genes.151 Myriad, being the only entity permitted to use the genes,
charges more than $3,000 for its diagnostic test to determine whether an individual is
at risk for breast or ovarian cancer.152 While this is a strong argument against
monopolies created by gene patents, in essence, all patents create a monopoly due to
the basic concepts patents are based upon.153

151

Pollack, supra note 131.

152

Pollack, supra note 131. While Myriad Genetics retained its monopolies over the
BRCA1 and BRCA2 genes, it is only a matter of time before Myriad has challenges to face
again. Andrew Pollack, Despite Gene Patent Victory, Myriad Genetics Faces Challenges, THE
N.Y. TIMES (Aug. 24, 2011), http://www.nytimes.com/2011/08/25/ business/despite-genepatent-victory-myriad-genetics-faces-challenges.html?_r=1&pagewanted=all. Experts believe
that the expensive testing will become incompetent and will be “outmoded, complete, and too
costly” as technological breakthroughs continue to occur. Id. Mary-Claire King, a professor of
genome sciences and medicine at the University of Washington argues that “Science has
moved beyond what these folks do. It’s not good for the science and it’s not good for the
patients and their clinicians if they cannot have the most complete, up-to-date information.”
Id. The new techniques used with DNA sequences are faster and cheaper than the technology
that Myriad developed in the 1990s. Id. Soon, for the same price that Myriad chargers for just
two genes, individuals will be able to have their entire genome sequence mapped -- about
22,000 genes. Id. Myriad executives counter that the company is preparing for the
technological changes. Id. Executives also point out that the “company’s patent protection
should last until at least 2018,” which will give the company the opportunity to adopt and
diversify the latest technology. Id. The company announced plans that it intends to rely less on
patents, and instead rely on trade secrets. Id. Myriad has done the most in terms of testing with
BRCA1 and BRCA2 genes, and it is more than likely that Myriad knows “which of the
thousands of possible mutations in the two genes actually raise the risk of cancer.” Id.
“Myriad used to share such information with a public database maintained by the National
Institutes of Health, and it cooperated with academic scientists trying to analyze the mutations
[; however,] a few years ago, the company quietly stopped contributing and cooperating, in
favor of building its own database.” Id. In 2006, Myriad developed a supplemental test,
known as the Comprehensive BRAC Analysis, that corrected issues from its previous test. Id.
The supplemental test cost $700, but insurers do not cover the cost, leaving many women
without the opportunity to obtain the test. Id. “More than 200 doctors, genetic counselors and
other health care professionals have signed an open letter to Myriad urging it to incorporate
the supplemental testing into the main test.” Id. For example:
Kathleen Maxian says that if that had been done earlier, she might not be fighting for
her life against ovarian cancer. Her sister developed breast cancer at age 40 about five
years ago, but tested negative for mutations on Myriad’s main test. She was not
offered the supplemental test. Two years ago, Ms. Maxian developed ovarian cancer.
It turned out that both she and her sister had genetic alterations that were detectable
only by the supplemental test. ‘If my sister had had that test and had gotten a positive
result, I would have gone to a genetic counselor and have been tested,’ said Ms.
Maxian, who is 49 and lives in Pendleton, N.Y., near Buffalo. She would then have
had the option of having her ovaries removed to avoid getting ovarian cancer. ‘I don’t
want to see this happen to anyone else,’ she said. ‘Women should have this test.’
Id.
153
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In Kewanne Oil Co. v. Bicron Corp., the Supreme Court justified the purpose of
patents “to provide incentives for inventiveness and research efforts.”154 It was the
intentions of the Framers’ to grant temporary exclusive rights to researchers for their
discoveries to further promote research and development and allow rewards for
researchers.155 Monopolies are inevitable with the use of not only gene patents but
patents in general. Monopoly can be defined as an “exclusive ownership through
legal privilege.”156 A patent as defined by Merriam-Webster, is “a: a writing securing
for a term of years the exclusive right to make, use, or sell an invention [or] b: the
monopoly or right so granted.”157 By granting an individual the exclusive right over
their discovery, a monopoly is automatically created. Therefore if opponents to gene
patents wish to eliminate the monopolies created by patents in entirety, the concept
of patents would have to be eliminated, which goes against the intentions of the
Framers’.
ii. The Effects on Science and Genetic Research
Proponents of gene patents argue that scientific research and discoveries are
amplified with the use of gene patents, while opponents argue that gene patents place
a significant hold and block on the collaborative basis for which scientific research
occurs.158 Both sides of the debate are correct in their analysis; however, both
aspects are needed to further promote scientific research and scientific
breakthroughs. This concept will be further analyzed in Part IV of this Note.
iii. Patenting an Aspect of Nature
Whether genetic material can be categorized as patentable subject matter in
connection with 35 U.S.C. § 101, has been a topic of much debate since the 1980s.
The Ass’n for Molecular Pathology is the most recent case that demonstrates the
judicial stance on gene patents as patentable subject matter within scope of 35
U.S.C. § 101.159 With both the courts and the USPTO support of gene patents for
almost thirty years, it is unlikely that the norm will change.160 In its recent grant of
certiorari in the Ass’n for Molecular Pathology, the Supreme Court will likely affirm
the court of appeals decision and permit isolated DNA sequences as patentable
154
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subject matter as it has been the protocol since Chakrabarty.161 Changing the
standard by which scientists and the biomedical industry have come accustomed to
since 1980 and the holding in Chakrabarty, a loss for Myriad could significantly hurt
the biomedical industry and scientific progress.162
The purpose of this Note is not to analyze whether genetic material is patentable
subject matter under 35 U.S.C. § 101. This Note is written following the latest
judicial decision in Ass’n for Molecular Pathology, in addition to the historical
stance the USPTO and the courts have followed, in finding that genetic material is
patentable subject matter under 35 U.S.C. § 101. The remainder of this Note
addresses whether the new Leahy-Smith America Invents Act (“AIA”) implements
the expressed societal concerns surrounding gene patent regulations, and examines
changes that need to be implemented to promote scientific research and collaboration
that will foster more timely results in diagnostic technologies and treatments.
IV. LEAHY-SMITH AMERICA INVENTS ACT (“AIA”)
The AIA is the first major reform to the United States patent law system since
1952.163 The AIA, while narrow in scope, keeps the basic structure of the U.S. patent
system by implementing numerous changes to promote efficiency and structure.164
While the AIA does promote new changes and advances in the U.S. patent system,
the AIA does not address the concerns established by critics of gene patents that
grew from the Patent Act of 1952 and the recent explosion in genetic research.165
Before criticizing the AIA for neglecting to implement procedures and regulations
specifically designed for gene patents, a thorough overview on the new legislation
must be provided.
The AIA harmonizes the U.S. patent system with other patent systems
established in Europe and other countries by implementing a first-inventor-to-file
system (“FITF”).166 The AIA also addresses issues that have negatively impacted the
U.S. patent system. The AIA amends the “joinder standard for joining defendants in
a patent infringement action and eliminat[es] qui tam false marking actions
entirely.167 In addition to implementing the FITF system, the AIA also promotes
161

Kendall, Supra note 137.

162

Kendall, Supra note 137.

163

Erick Bensen, Erick E. Bensen on the America Invents Act, 2011 EMERGING ISSUES
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change patent litigation, WESTLAW JOURNAL INTELLECTUAL PROPERTY, Nov. 18, 2011,
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faster patent processing, implements a new derivation proceeding, and revamps the
post-patent review proceedings.168
A. Patent Processing
1. First-Inventor-to-File
A major change the AIA makes to the U.S. patent system is the conversion from
a first-to-invent system to a first-inventor-to-file (“FITF”) system.169 Changing the
U.S. patent system to the FITF system harmonizes the U.S. patent system with the
European patent system, giving American inventors more protection abroad by
making the patent process more efficient, predictable, and in accords with foreign
guidelines.170 The adoption of the FITF system will be officially implemented
eighteen months from the date President Obama signed the AIA into law.171 During
this eighteen-month period, the AIA calls for two studies to be performed.172 The
first study is designed to look into the effect the FITF system will have on small
businesses, while the second study determines whether the U.S. should implement a
“prior user rights.”173 The delay will allow Congress to assess the findings of the two
studies to determine if and what change need to be made to the FITF system.174
i. Changes Made by the FITF System
The AIA changes the language of the old first-to-invent system to the FITF
system by amending the language to state “that a person shall be entitled to a patent
unless it was made available to the public, sold, or offered for sale anywhere in the
world, or patented or described in a publication before the effective filing date of the
claimed invention.”175 With the new system, patents and published patent
applications become “prior art” on the “effective filing date” of the patent or patent
application.176 “Effective filing date” is defined by the AIA “as the actual filing date
of an application or the filing date of the earliest application for which the patent or
a product was popular among the public. Id. Under the new regulations implemented by the
AIA, only the United States government will be able to sue for damages for false marking. Id.
“Private parties will be entitled only to compensatory damages based on ‘competitive injury
flowing from the false marking.” Id. This new legislation will apply to pending cases, as well
as on cases that were commenced on or after the enactment of the AIA. Id. It is likely, that
because of these new regulations, that false marking cases will become rare in the future. Id.
168
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application is entitled for that invention.”177 The implementation of a FITF system
will end the need for expensive discovery and litigation over priority dates because
inventors will now be able to establish priority dates by filing an inexpensive, simple
application.178
ii. Exceptions to the FITF System
The FITF system has two main exceptions.179 The first exception entitles
inventors “to a one year grace period for disclosures made by the inventor or by one
who obtained the disclosed information from the inventor.”180 The AIA, however,
does not define the term “disclosure.”181 The definition will likely be left to the
courts to determine, as it will more than likely be a topic of early-litigated actions.182
The second exception excludes “narrow categories of patents and published
applications that encompass [an] inventor’s own work.”183 These narrow categories
incorporate patents and applications that release information acquired by the
inventor, information that was described in a publication by the inventor, or
information that was owned or assigned to a common owner.184 An example of work
that may fall within the second exception would be information developed from a
joint research agreement between two inventors.185 In addition to changing the patent
system to FITF system, the AIA also changes the rights of third parties.
2. Submissions by Third Parties
Before the AIA, under the former patent legislation, third parties had limited
input with the patent application process.186 Now, under the AIA, “any third party
may submit prior art for consideration and inclusion in the record of a patent
application.”187 Prior art can be defined to be “any patent, published patent
application, or other printed publication of potential relevance to the examination of
the application.”188 A submission of prior art by a third party must be made in
177
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writing within six months of the application publication.189 The submission “must
set forth a concise description of the asserted relevance of each submitted
document.”190 Along with the rights of third parties being recognized, the AIA also
changed the means by which an applicant inventor can make an oath.
3. Inventors Oath
Pursuant to the prior patent legislation, “applicants were required to provide an
oath or declaration of each applicant inventor stating that the applicant ‘believed
himself to be the original and first inventor of the process, machine, manufacture, or
composition of matter, or improvement thereof for which he solicits a patent.’”191
Now, under the AIA, a modification in the provision has been amended for applicant
inventors that are “deceased, under legal capacity, can not be found after diligent
effort, or [are] under obligation to assign the invention but [have] refused to make
oath or declaration.”192 In such circumstances, the AIA has given the option for an
applicant inventor to substitute a statement in lieu of an inventor oath or
declaration.193 While making some positive changes, the AIA has also prohibited a
few means of former patentable subject matter.
4. Tax Strategies with Patent Applications
Under former patent legislation, individuals could obtain patents for “tax
strategies for lowering or reducing tax liability.”194 Under the AIA, such patent
applications are prohibited, “by defining such an invention, including any strategy
for reducing, avoiding, or deferring tax liability…as deemed insufficient to
differentiate a claimed invention from the prior art.”195
5. Human Organisms
Under former U.S. patent legislation, it was the USPTO’s policy to reject patent
applications or claims regarding human organisms.196 The AIA has codified this
policy, formerly known as MPEP § 2105, by establishing that “human organisms
[were] not patentable subject matter.”197 An organism is “[a]n individual living thing
that can react to stimuli, reproduce, grow, and maintain homeostasis.”198 Pursuant to
189
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198

Organism, BIOLOGY ONLINE, http://www.biology-online.org/dictionary/Organism (last
visited Feb. 20, 2013).

2013]

MAPPING OUR FUTURE

401

the definition of organism, the prohibition on human organism patents by the AIA
does not include gene patents because (1) genes are merely a sequence of nucleotides
(a segment of DNA) found on a chromosome that is part of an organism, and (2)
genes cannot react to stimuli, grow, or reproduce.199 Thus, gene patents are still
untouched by the prohibitions established by the AIA.
6. Prioritized Examination
Under the AIA, the USPTO provides a “prioritized examination” option, in
which individuals can purchase “prioritized examination” upon filing a patent
application.200 An application with “prioritized examination” gives an application
“special status” in order for the application to be advanced through the USPTO’s
examination process.201 This “special status” allows applications to be processed at
a faster rate so that a final disposition can be granted within twelve months of the
priority examination date.202 Status can be granted through one of the following:
•
•
•
•
•
•

“[m]ailing of a notice of allowance;”203
“mailing of a final Office action;”204
“filing of a notice of appeal;”205
“completion of examination as defined in 37 C.F.R. 41.102;”206
“filing of a request for continued examination; or”207
“abandonment of the application”208

In addition to a fee for prioritized examination, applicants still must pay the
ordinary filing fee, search fee, and other miscellaneous fees.209
One of the
goals of the AIA is to implement an overall faster patent process.
7. Faster Patent Processing
The AIA has a twelve-month guarantee for patent processing, which significantly
decreases patent processing from an average of three years, and thus aids in the
reduction of the present patent backlog.210 Currently, the backlog has been reduced
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to 680,000 from 750,000 despite a 4% increase in filings.211 Horacio Gutierrez,
Microsoft’s deputy general counsel for intellectual property and licensing,
commented that the changes the AIA makes “‘will ensure that innovators in our
troubled economy can benefit from a predictable and rational patent system, with
new tools to eliminate patents that should not have been issued and to speed the
processing of patents that should be issued.’”212 In connection with implementing the
FITF system and decreasing the patent processing time period, the AIA also
establishes a new protective proceeding for inventors.
8. Derivation Proceedings
The AIA’s implementation of the derivation proceedings eliminates the U.S.
patent systems’ previously used process of interferences.213 Derivation proceedings
determine whether a patented invention was derived from the work of another
patented invention or patent application.214 These proceedings can be heard in two
different systems depending on the particular issues.215 If the conflict arises between
two different patents, the hearing will proceed in district court.216 If the conflict
arises between a patent and an application or two different applications, the
proceedings will occur at the USPTO in front of the Patent Trial and Appeal
Board.217 In addition to providing changes with filing, processing and initial legal
proceedings, the AIA also implements new plans for post-patent proceedings.218
B. Post-Patent Proceedings and Review
The AIA brings numerous changes to the U.S. patent systems standard of review
for granted patents.219 While the AIA retains reissue and Ex Parte Reexamination
proceedings enacted from previous patent acts, it replaces the Inter Partes
Reexaminations with the Inter Partes Review, and adds two additional proceedings,
the Post Grant Review and the Supplemental Examination proceedings, to the U.S.
patent system.220
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1. Inter Partes Review
Congress introduced the inter partes reexamination principle in the
Reexamination Act in 1980.221 The purpose of the inter partes reexamination
principle was to “‘strengthen investor confidence in the certainty of patent rights by
establishing a system of administrative reexamination of doubtful patents.’”222 While
the new inter partes review upholds the baseline of the previous process, the new
proceeding changes when a petition for review can be filed.223 Under the AIA, a
petition for review can be filed nine months after a patent has been granted or if a
post grant review has commenced, a petition can be filed after a decision has been
reached.224 The inter partes review also implements a new standard of review, which
analyzes whether a reasonable likelihood exists that the petitioner will prevail in
respect to one of the challenged claims.225 In addition, the AIA also seeks to speed
up the inter partes review process, an underlying theme seen throughout the AIA.226
Similar to the inter partes review, the post grant review system implemented by the
AIA seeks to challenge the validity of patents.227
2. Post Grant Review
The AIA created a new proceeding, post grant review (“PGR”), “where third
parties are able to challenge the validity and scope of an issued patent.”228 Prior to
the AIA, individuals were limited to challenge patents solely based on obviousness
and novelty, and based upon “prior patents or printed publications.”229 Under PGR,
an individual can challenge a patent on any ground of patentability and is not limited
to prior art patents and printed publications.230 PGR can be implemented in two
circumstances.231 First, PGR can be implemented if the information in the petition
demonstrates that one of the challenged claims is more likely than not patentable.232
Secondly, PGR can be implemented if the petition raises a novel or unsettled legal
question that is important to other similar patents and patent applications.233 A PGR
must be filed within nine months of the issuance of the patent or “issuance of a
221
Roger Shang, Inter Partes Reexamination and Improving Patent Quality, 7 NW. J. TECH.
& INTELL. PROP. 185, 186 (2009).
222

Id. (quoting Kaufman v. Lantech, 807 F.2d 970, 976 (Fed. Cir. 1986) (citing H.R. REP.
NO. 96-1307, pt. 1, at 3-4 (1980)).
223

John E. Schneider, supra note 166.

224

John E. Schneider, supra note 166.

225

John E. Schneider, supra note 166.

226

John E. Schneider, supra note 166.

227

John E. Schneider, supra note 166.

228

1 Pat. L. Fundamentals § 1:37 (West 2013).

229

Id.

230

Id.

231

John E. Schneider, supra note 166.

232

John E. Schneider, supra note 166.

233

John E. Schneider, supra note 166.

404

JOURNAL OF LAW AND HEALTH

[Vol. 26:375

broadening reissue.”234 A petitioner must chose between challenging a patent with
either the USPTO or the courts.235 The AIA does not establish specific rules
concerning the “rules of conduct” for the PGR; instead the AIA left the USPTO the
responsibility of developing the rules.236 In addition to creating the PGR
proceedings, the AIA also establishes Supplemental Examination proceedings.
3. Supplemental Examination
Supplemental examination allows a patent owner the ability to address any
validity issues that may have been uncovered after the patent had been granted.237
This process begins after a patent owner files a petition with the USPTO “raising at
least one new substantial question of patentability.”238 If the USPTO finds that the
owner of a patent has raised a substantial question of patentability, then the patent
will be examined under the procedures for ex parte reexamination.239 Ex parte
reexamination provides patent owners and third parties the ability to request the
USPTO to reconsider patents that are based on pre-existing technology that was not
initially reviewed.240 The USPTO only reexamines patents that propose a new
substantial question that needs to be reviewed.241 While making substantial changes
and improvements to the U.S. patent system with the implementation of the FITF
system, faster patent processing, the creation of derivation proceedings, and the
reworking of the post patent processing, the AIA does not address or implement new
guidelines specifically designed to regulate gene patents.
C. Litigation
1. Defenses to Infringement Cases
Under the AIA, the “prior use” defense, which originally was only permitted for
business method patent cases, is expanded as a defense for patent infringement for
all patent types.242 The prior use defense prohibits patent infringement243 claims
against individuals that show that (1) “they acted in good faith;” (2) “they actually
reduced the subject matter of a patented invention to practice at least one year before
the patentee filed its patent application;” and (3) “they commercially used that
subject matter before the patentee filed its patent application.”244
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2. Joinder of Parties in Infringement Litigation Cases
While expanding the scope of infringement cases, the AIA limits the number of
joinder of parties in infringements cases.245 A plaintiff that is related to the parties in
a single suit can only join lawsuits filed on or after the date of enactment.246 This
limit is implemented to require separate lawsuits to allow defendants to have an
easier means to seek venue transfer.247
3. Venue
Under the AIA, venue for patent litigation involving the USPTO has been
changed.248 Previously, patent litigation cases were filed in the U.S. District Court
for the District of Columbia.249 Now, pursuant to the AIA, cases are to be filed in
the U.S. District Court of the Eastern District of Virginia,250 specifically for cases
filed under the following sections:
•
•
•
•

“Section 32 related to disciplinary proceedings against patent
practitioners;”251
“Section 145 related to civil actions to obtain a patent;”252
“Section 154(b) related to patent term adjustment;”253 and
“Section 146 related to civil actions in interference cases actions
against a foreign patent owner”254

In addition to changing venue for particular patent cases, the AIA also narrowed
the scope of false marketing cases.
4. Advice of Counsel Defense
Under the AIA, if a defendant in a patent infringement lawsuit fails to obtain
advice of legal counsel, such failure “cannot be used to prove that the defendant
willfully infringed the patent” at issue.255
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5. False Marketing Cases
Prior to the AIA, any person could sue for false marketing under the false
marketing statute qui tam provision.256 The AIA eliminates false marketing lawsuits
for “any person,” except for cases filed by a competitor who can prove competitive
injury or the U.S. government.257 This provision of the AIA applies retroactively
from the date of enactment.258
D. The AIA’s Answers for Gene Patents and Scientific Research
While the AIA implemented numerous new initiatives and protocols to revamp
the U.S. patent system, gene patents were not included in the overall master plan.
On the same day that the AIA was officially signed into law by President Obama,
plans were announced for the development of a national bioeconomy blueprint by
January 2012.259 The Obama Administration announced a plan to create a
bioeconomy blueprint that will detail “[a]dministration-wide steps to harness
biological research innovations to address national challenges in health, food,
energy, and the environment.”260
Biological research, specifically genetic research, plays a significant role in the
United States’ economy and the well being of Americans.261 To ensure that this trend
continues, the bioeconomic blueprint is intended to “focus on reforms to speed up
commercialization and open new markets, strategic [research and development]
investments to accelerate innovation, regulatory reforms to reduce unnecessary
burden on innovators, enhanced workforce training to develop the next generation of
scientists and engineers, and the development of public-private partnerships.”262
In addition to the bioeconomic blueprint, the National Institute of Health (“NIH”)
will be launching a program aimed to assist biotechnical entrepreneurs.263 The NIH
plans to establish a National Center for Advancing Translational Sciences
(“NCATS”) that will identify barriers in the way of scientific progress, such as
financial barriers.264 Though it appears that the Obama Administration, through the
AIA, is taking initiative to promote genetic research and to foster scientific progress,
in reality, separate regulations in conjunction with the AIA are required to establish
specific guidelines for gene patents to promote scientific research and collaboration,
which will ultimately result in faster diagnostic and health discoveries.
Overall, the AIA implements positive changes to the U.S. patent system;
however, the AIA failed to establish guidelines specifically designed to regulate
gene patents. Gene patents have been a topic of controversy since the Supreme
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Court’s decision in Chakrabarty.265 Numerous concerns have been raised through
case law and scholarly articles outlining the issues that need to be addressed by
legislation.266 Instead of correcting the problem, the AIA has remained silent. The
answer is not to conduct more studies and launch separate programs in conjunction
with the AIA to develop “blueprints” for genetic and scientific research as suggested
by the Obama Administration. The time for action is now. Genetic research can and
will lead to the discovery of new diagnostic treatments and cures; cures that could
have saved Kathy Hopkins and Greg Knittel. The answers that genetic research can
provide society are eminent, and the discoveries genetic research can provide to
healthcare services is potentially world changing. Gene patents should be
categorized in a separate patent category within the AIA, under regulations
specifically designed to promote scientific research and collaboration that will in
turn foster faster results for diagnostic technologies and treatments.
V. THE IMPACTS OF GENE PATENTS ON SCIENTIFIC RESEARCH AND THE NEED FOR
LEGISLATIVE GUIDELINES
The U.S. patent system needs to be adapted for the rapidly changing field of
genetics by implementing new regulations for gene patents specifically designed to
promote scientific research and collaboration.267 To adapt for the rapidly changing
field of genetics, the AIA, and thus the U.S. patent system, should be amended to
implement the following regulations specifically geared for gene patents:
(1) establish a new patent category specifically engineered for gene
patents;
(2) reduce the period of gene patent protection to promote collaboration
among researchers and foster faster research results;
(3) require individuals with patents to share their research on the
GenBank database to further promote collaboration and render faster
results; and lastly,
(4) implement patent pooling as another mechanism to promote
collaboration and increase discovery rates.
Each proposal will be discussed in detail below.
A. The Creation of a New Patent Category: Gene Patents
Instead of categorizing and regulating gene patents under the same guidelines as
utility patents, separate legislation should be implemented to categorize and regulate
gene patents as separate entities. Currently, the patent system only identifies three
categories of patents: (1) utility patents, (2) design patents, and (3) plant patents.268
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Gene patents are a subcategory under utility patents.269 Plant patents are given to
inventors that have “invented or discovered and asexually reproduced a distinct and
new variety of plant, other than a tuber propagated plant or a plant found in an
uncultivated state.”270 To invent or discover a “distinct and new variety of plant” that
is not found in nature, researchers must use plant DNA, similar to the process
researchers use to extract gene sequences from human DNA.271
Arguably, if plant patents are categorized as a separate patent type, gene patents
should be categorized as a separate patent type as well.272 If the USPTO allows
researchers to patent extracted plant DNA gene sequences that are not found in
nature as regulated by plant patents, then gene patents should be categorized in a
similar fashion since the underlying techniques and scientific mechanisms are so
similar. Therefore, the AIA should, using the plant patent category as a model,
establish a fourth patent category specifically engineered to regulate and promote
gene patents.
B. A Reduction in Patent Protection to Implement Collaboration
In addition to creating a fourth patent category for gene patents, additional
guidelines should be established to implement a shorter protection period to promote
scientific collaboration, and in turn, stimulate faster discoveries. To achieve the
maximum benefits from research, a collaboration system must be implemented to
emphasize the need for data sharing.273
As stated by the National Research Council (NRC) in 2003:
Community standards for sharing publication-related data and materials
should flow from the general principle that the publication of scientific
information is intended to move science forward. More specifically, the
act of publishing is a large quid pro quo in which authors receive credit
and acknowledgement in exchange for disclosure of their scientific
findings. An author’s obligation is not only to release data and materials
to enable others to verify or replicate published findings but also to
provide them in a form on which other scientists can build with further
research. All members of the scientific community – whether working in
academia, government, or a commercial enterprise – have equal
responsibility for upholding community standards as participants in the
269
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publication system, and all should be equally able to derive benefits from
it.274
Collaboration is a key element to the success of scientific research. Patents by
definition “exclude others from making, using, offering for sale, or selling [an]
invention [in] the United States.”275 Both utility patents and plant patents provide
twenty years of protection.276 Only when the patent expires does the patented
subject matter become public domain.277 Legally excluding others from making or
using a patented sequence for twenty years significantly prohibits the progression of
science and the discovery of diagnostic techniques and treatments for diseases, such
as cancer and ALS.
It is unnecessary to exclude the scientific community from working with patented
gene sequences for twenty years. Two of the main reasons scientists seek patents are
for recognition of their work and to preserve the opportunity to continue working
with their discovery or invention without the pressure of competition. Neither of
these functions requires twenty years of protection. Instead of granting a long term
274
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of protection, the period of protection should be shortened to ten years with the
opportunity for researchers to renew for an additional five years pursuant to
substantial evidence of significant research development, otherwise the term ends,
and the patented subject matter becomes public domain.
The HGP was planned to last fifteen years but only took thirteen years.278 The
key to the success of the HGP was collaboration. If the HGP, through a collaborative
effort, discovered 20,500 genes of the human genome, then it is reasonable to
assume that any researcher, through collaborative efforts, can make substantial
progress in research to renew patent protection for an additional five years.279 If a
researcher cannot provide evidence to show substantial progress then the patented
gene sequence should become public domain to give others the opportunity to study
the previously patented subject matter.
C. GenBank Database
In addition to creating a new category for gene patents and reducing the duration
of patent protection to further promote collaboration and scientific progress,
Congress should implement the GenBank database as a mandatory system within the
U.S. gene patent system.280 The GenBank is a free, public database sponsored by the
NIH that houses genome sequences generated by the HGP, the HapMap Project, and
other scientific research.281 The NIH designed the GenBank “to provide and
encourage access within the scientific community to the most up to date and
comprehensive DNA sequence information.”282 By forcing all scientists that obtain a
gene patent through USPTO to upload their research and findings as they progress
through the protected patent period to GenBank, a complete international database
will exist that will influence not only patented projects, but this data base will also
spark new findings and inventions for new patents.
GenBank is the key to implementing collaboration into a system that has
historically and legally prevented it.283 Currently, the NIH has “no restrictions on the
278
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use or distribution of the GenBank data” and has no means of assessing claims of
patented intellectual property.284 The NIH “cannot provide comment or unrestricted
permission concerning the use, copying, or distribution of the information contained
in GenBank.”285 This problem can easily be fixed by requiring users to register
before being able to use the database, tracking the specific sequences and the
frequency of each user, tracking the contributions users upload, and requiring users
with patents to provide proof upon submittal, and in turn clearly marking patented
submissions as patent protected work.286 Protecting patented work and allowing
researchers to share research in a free, open, and protected environment will allow
for significant progress in diagnostic and treatment technologies that will save
millions of lives.
D. Patent Pooling
Potential ramifications of the GenBank database in terms of collaboration include
the desire of other researchers to partake in a patented project. To allow for such
occurrences, the USPTO should implement gene patent pooling within the
regulations of gene patents.287 “A patent pool is an agreement between two or more
patent owners to license one or more of their patents to one another or third
parties.”288 Patent pooling can alternatively be defined as “the aggregation of
intellectual property rights which are the subject of cross-licensing, whether they are
the last two years. Approximately 40 percent of industry respondents and 69 percent
of academic scientists had received such a request in the same period. Rates of
initiation and receipt of requests are about the same for those doing drug discovery
and those doing basic research.
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transferred directly by patentee to licensee or through some medium, such as a joint
venture, set up specifically to administer the patent pool.”289
Patent pools have played an important role within the U.S. patent system for over
150 years.290 There is no conceivable reason why this form of patent cannot be
implemented within gene patent regulations. Patent pools offer greater innovation
because more individuals can work with patented subject matter.291 This permits
parallel research because both the patented researcher and the licensed researchers
can study a patented subject matter, which results in faster discoveries and results.292
Patent pooling within the realm of gene patents will only further promote scientific
research and collaboration.
The AIA needs to be amended to include legislation, as described above, to better
regulate gene patents.293 The goals of gene patents should not be focused on name
recognition or monetary purposes but instead on discovering diagnostic tools and
treatments that will save millions of lives. By implementing guidelines that promote
collaboration and scientific research, vast innovations and breakthroughs will occur
and will bring about diagnostic tools and treatments.
VI. CONCLUSION
The AIA is the foremost change in the U.S. patent system since 1952.294 While
the AIA implements many new regulations within the U.S patent system, no
regulations were established to better regulate gene patents.295 The Obama
Administration announced several plans and studies to look into the proper
regulations for gene and biotechnology; however, this research is not needed as gene
patents have been a topic of debate within intellectual property, science, and health
care for the past three decades.296 Instead of wasting more time researching the best
289
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practices to regulate gene patents, stricter guidelines need to be implemented within
the AIA to regulate gene patents, and this implementation needs to occur quickly to
keep up with the rapidly growing field of genetics.297
In order for the U.S. patent system to keep up with the rapidly growing field of
genetics, the following suggestions should be implemented into the AIA to enforce
stricter guidelines for gene patents: (1) a new category within the patent system
should be created specifically for gene patents, as modeled from plant patents;298 (2)
the period of gene patent protection should be reduced from twenty years to ten
years, with the potential to renew for an additional five years through a showing of
substantial scientific progress, to promote collaboration and faster results as seen
through the HGP;299 (3) individuals that acquire gene patents must be required to
share their research on the GenBank database to further promote collaboration and
faster results, not only within the United States, but also internationally;300 and, (4)
the AIA needs to implement patent pooling for gene patents as a means to support
collaboration and the use of the GenBank, as well as promote faster results.301 By
implementing such regulations into the AIA, more scientific breakthroughs will
occur, which will result in the discovery of new diagnostic technologies and
treatments, and in turn will save millions of lives from common diseases that were
once deemed incurable.
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